Institute of Experimental Pharmacology and Toxicology, Medical Faculty Mannheim, Heidelberg University, Germany.
J Mol Cell Cardiol. 2012 Aug;53(2):165-75. doi: 10.1016/j.yjmcc.2012.04.015. Epub 2012 May 4.
Activation of α(1)-adrenoceptors (α(1)-AR) by high catecholamine levels, e.g. in heart failure, is thought to be a driving force of cardiac hypertrophy. In this context several downstream mediators and cascades have been identified to potentially play a role in cardiomyocyte hypertrophy. One of these proteins is the monomeric G protein Rac1. However, until now it is unclear how this essential G protein is activated by α(1)-AR agonists and what are the downstream targets inducing cellular growth. By using protein-based as well as pharmacological inhibitors and the shRNA technique, we demonstrate that in neonatal rat cardiomyocytes (NRCM) Rac1 is activated via a cascade involving the α(1A)-AR subtype, G(i)βγ, the phosphoinositide-3'-kinase and the guanine nucleotide exchange factor Tiam1. We further demonstrate that this signaling induces an increase in protein synthesis, cell size and atrial natriuretic peptide expression. We identified the p21-activated kinase 2 (PAK2) as a downstream effector of Rac1 and were able to link this cascade to the activation of the pro-hypertrophic kinases ERK1/2 and p90RSK. Our data thus reveal a prominent role of the α(1A)-AR/G(i)βγ/Tiam1-mediated activation of Rac1 and its effector PAK2 in the induction of hypertrophy in NRCM.
高儿茶酚胺水平(如心力衰竭时)激活 α(1)-肾上腺素受体(α(1)-AR)被认为是心肌肥厚的驱动力。在这种情况下,已经确定了几个下游介质和级联反应,它们可能在心肌细胞肥大中发挥作用。这些蛋白质之一是单体 G 蛋白 Rac1。然而,直到现在,人们还不清楚这种必需的 G 蛋白如何被 α(1)-AR 激动剂激活,以及哪些下游靶标诱导细胞生长。通过使用基于蛋白质的药理学抑制剂和 shRNA 技术,我们证明在新生大鼠心肌细胞(NRCM)中,Rac1 通过涉及 α(1A)-AR 亚型、G(i)βγ、磷酸肌醇-3'-激酶和鸟苷酸交换因子 Tiam1 的级联反应被激活。我们进一步证明,这种信号转导诱导蛋白质合成、细胞大小和心钠肽表达增加。我们鉴定出 p21 激活激酶 2(PAK2)作为 Rac1 的下游效应物,并能够将这种级联反应与促肥大激酶 ERK1/2 和 p90RSK 的激活联系起来。因此,我们的数据揭示了 α(1A)-AR/G(i)βγ/Tiam1 介导的 Rac1 及其效应物 PAK2 在 NRCM 诱导肥大中的重要作用。